Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety

Central nervous system (CNS) tumors are the most common solid malignancy in the pediatric population. Based on adoptive cellular therapy's clinical success against childhood leukemia and the preclinical efficacy against pediatric CNS tumors, chimeric antigen receptor (CAR) T cells offer hope of...

Full description

Saved in:
Bibliographic Details
Published in:Neoplasia (New York, N.Y.) N.Y.), 2023-02, Vol.36, p.100870-100870, Article 100870
Main Authors: Vitanza, Nicholas A., Ronsley, Rebecca, Choe, Michelle, Henson, Casey, Breedt, Mandy, Barrios-Anderson, Adriel, Wein, Amy, Brown, Christopher, Beebe, Adam, Kong, Ada, Kirkey, Danielle, Lee, Brittany M., Leary, Sarah E.S., Crotty, Erin E., Hoeppner, Corrine, Holtzclaw, Susan, Wilson, Ashley L., Gustafson, Joshua A., Foster, Jessica B., Iliff, Jeffrey J., Goldstein, Hannah E., Browd, Samuel R., Lee, Amy, Ojemann, Jeffrey G., Pinto, Navin, Gust, Juliane, Gardner, Rebecca A., Jensen, Michael C., Hauptman, Jason S., Park, Julie R.
Format: Article
Language:English
Subjects:
B7-H3
Brain Neoplasms - pathology
Catheters
Central nervous system (CNS) tumor
Central Nervous System Neoplasms - therapy
Child
Chimeric antigen receptor (CAR) T cells
CNS catheter
EGFR
HER2
Humans
Immunotherapy, Adoptive - adverse effects
Immunotherapy, Adoptive - methods
Ommaya
Pediatric Brain Tumor
T-Lymphocytes
Ventriculoperitoneal (VP) shunt
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Central nervous system (CNS) tumors are the most common solid malignancy in the pediatric population. Based on adoptive cellular therapy's clinical success against childhood leukemia and the preclinical efficacy against pediatric CNS tumors, chimeric antigen receptor (CAR) T cells offer hope of improving outcomes for recurrent tumors and universally fatal diseases such as diffuse intrinsic pontine glioma (DIPG). However, a major obstacle for tumors of the brain and spine is ineffective T cell chemotaxis to disease sites. Locoregional CAR T cell delivery via infusion through an intracranial catheter is currently under study in multiple early phase clinical trials. Here, we describe the Seattle Children's single-institution experience including the multidisciplinary process for the preparation of successful, repetitive intracranial T cell infusion for children and the catheter-related safety of our 307 intracranial CAR T cell doses.
ISSN:1476-5586
1522-8002
1476-5586
DOI:10.1016/j.neo.2022.100870